Mechanistic description
TDP-43 undergoes pathological liquid-liquid phase separation in ALS/FTD, and small molecules that restore liquid-like properties could theoretically address both nuclear loss-of-function and cytoplasmic gain-of-function toxicity. However, this hypothesis faces fundamental barriers: no defined binding pocket exists for intrinsically disordered regions, distinguishing pathological from physiological LLPS remains unsolved, and no validated biomarker exists for target engagement. Precedent failure of aggregation-targeting strategies (tau inhibitors in AD) suggests this approach may not translate.
Mechanism / pathway
- TARDBP
- neurodegeneration
Evidence for (3)
TDP-43 pathology present in ~95% of ALS cases and ~50% of FTD
TDP-43 mutations cause familial ALS
Phase separation properties of TDP-43 C-terminal domain critical for pathology
Evidence against (2)
TDP-43 aggregation may be protective sequestration - not causative
TDP-43 haploinsufficiency alone causes neurodegeneration
Evidence matrix
Supporting
- TDP-43 pathology present in ~95% of ALS cases and ~50% of FTD PMID:29700312
- TDP-43 mutations cause familial ALS PMID:19479329
- Phase separation properties of TDP-43 C-terminal domain critical for pathology PMID:29483654
Contradicting
- TDP-43 aggregation may be protective sequestration - not causative PMID:28017329
- TDP-43 haploinsufficiency alone causes neurodegeneration PMID:25678559
Cite this hypothesis
Cite this hypothesis
envelope-repair (2026). Rational design of small molecules targeting TDP-43 liquid-to-solid phase trans…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-fc57d8e73d
@misc{scidex_hypothesis_hfc57d8e,
title = {Rational design of small molecules targeting TDP-43 liquid-to-solid phase trans…},
author = {envelope-repair},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-fc57d8e73d},
note = {SciDEX artifact hypothesis:h-fc57d8e73d}
}